财务部 | OA
Brief Introduction to SZPTRI-NJU
Brief Introduction to
Shenzhen Pharmaceutical Technology Research Institute of Nanjing University
1. Profile
Shenzhen Pharmaceutical Technology Research Institute is affiliated with Shenzhen Research Institute of Nanjing University and
co-founded in Shenzhen, among Shenzhen Research Institute of Nanjing University, the State Key Laboratory of Pharmaceutical
Biotechnology of Nanjing University, HLK Pharmaceuticals Co., Ltd., and HLK Biotechnology Co., Ltd in November of 2013.
It combines the technical expertise and industrial experience in HLK with the academic strength and research capability of
NanjingUniversity. With the consolidation of global expertise in pharmaceutical research and development, the goal of the institute
is to promote technology exchanges between East and West, provide cutting age pharmaceutical development technologies to develop
and manufacture new pharmaceutical products, as well as advance the development of traditional Chinese medicines according to the
current development standards and regulations in Chinese and Western markets.
On November 15, 2013, a ceremony was held in Shenzhen Virtual University Park at the 2013
Virtual University Park association annual meeting.
The Pharmaceutical Technology Research Institute is located in Shenzhen Industry, Education and Research Base of Nanjing University,
Address: No. 6 Yuexing 3rd road, Southern District of Shenzhen High-tech Industrial Park, Nanshan District, Shenzhen, P.R. China.
The laboratory of the Institute is located in the Bio-Incubator of ShenzhenHigh-TechIndustrial Park
Address: 10 Gaoxin Central. 1ST Ave., Central District of Shenzhen High-tech Industrial Park, Nanshan District, Shenzhen, P.R. China
Management Team of Shenzhen Pharmaceutical Technology Research Institute of NanjingUniversity
2. Mission
Our mission is to bridge the technology advances between East and West, provide the best and affordable medicines for patients.
3. Organization
The Pharmaceutical Technology Research Institute is organized into six innovation centers:
(1) Novel Pharmaceutical Products Development Center
This center is responsible for the development of new chemical entities and new dosage forms of pharmaceutical products, following
the international development standards and regulations.
(2) Generic Pharmaceutical Product Development Center
This center is responsible for the development of generic pharmaceutical products in the therapeutic areas of cardiovascular, immune
disease and malignant tumor.
(3) Nature Pharmaceutical Product Development Center
This center is responsible for the development of nature pharmaceutical products with the focus of developing TCM (Traditional
Chinese Medicine) and botanic pharmaceutical products, with the advanced pharmaceutical technologies.
(4) Pharmaceutical Dosage Form Development Service Center
The center is responsible for providing services to international clients for the development of varies of pharmaceutical dosage forms.
(5) International Pharmaceutical Technology Exchange Center
This center is responsible to be a portal for pharmaceutical technology exchange, and particularly to be a portal for western companies
or entrepreneurs to develop pharmaceuticals for the China market.
(6) Medical Project Investment and Financing Center
This center is responsible to incubate medical projects and small micro enterprise or create entity companies by working with
NanjingUniversity, business service companies and VC/PE companies.
4. Management Team
(1) The Board of Directors
The Pharmaceutical Technology Research Institute of Nanjing University is under the leadership of the board. The board consists
of following five members.
Chairman of the Board, Yi PAN
|
Board Member, Xuyu ZHANG
Prior to this position, he was the Assistant President of Nanjing University and the Dean of Shenzhen Research Institute of Nanjing University.
|
Board Member, Zeren WANG
|
Board Member, Zichun HUA
Professor HUA is a Vice Dean of College of Life Science, Nanjing University. He is also the director of the State Key Laboratory of Pharmaceutical Biotechnology of Nanjing University, as well as the director of the Shenzhen R&D Section of the State Key Laboratory of Pharmaceutical Biotechnology of Nanjing University. He has been awarded National Outstanding Youth Fund in 2004, and Distinguished Professor for the Cheung Kong scholars program in 2010.
|
Board Member, Jun XU
|
Professor PAN is a Vice President of Nanjing University 
Professor ZHANG is now a Vice President of Nanjing Normal University. 
Dr. WANG is the co-founder, the Managing Director and CSO of HLK. In this position, he is responsible for the overall science and technical management of the company. He also is the adjunct researcher of the State Key Laboratory of Pharmaceutical Biotechnology of Nanjing University. He has over 15 years of experience in major international pharmaceutical companies (including Novartis and Boehringer Ingelheim) in drug dosage form development. He is specialized in formulation development of poorly water soluble compounds for oral delivery and experienced in the development of oral solid dosage forms (tablets, hard gelatin capsules, soft gelatin capsules), oral liquid dosage forms (solutions and suspensions), controlled release technology, and parenteral (lyophilization). He has 30 peer reviewed publications and patents, as well as numerous poster presentations.
Ms. XU is the co-founder and President of HLK. She is responsible for business development, strategy, customer relations, and interacting with governmental agencies and regulators. Jun also works with both Chinese and US-based companies and governments to promote mutual cooperation and business in the biotech and pharmaceutical sectors. Prior to her current position, Jun has over 15 years of experience in major international pharmaceutical companies (including Novartis and Boehringer Ingelheim) in drug discovery and development.
(2)The Secretariat
Secretary-general of the Secretariat, Dong HAN
|
Mr. HAN is the dean of the Shenzhen Research Institute of Nanjing University and the chief representative of Nanjing University for the Shenzhen Virtual University Park.
(3) The Executive Committee Members
This executive committee is responsible for the routine activities of the institute. It is also responsible for the decision making and management regarding technology, market, capital operation and the legal activities. The committee is operated under the supervision of the Board of Directors.
The committee is consisting of four following members: Executive Vice Dean, Dr. Zeren WANG; Vice Deans, Dr. Zichun HUA, Mr. Dong HAN and Ms. Jun XU.
(4) Scientific Expert Committee Members
Dr. Peter FARINA
Dr. FARINA is an Executive in Residence at Canaan Partners, a venture capital firm, located in Westport, CT where he assesses and advises on pharma/biotech/healthcare investments. He is also the managing partner of a consulting firm, Salient Science & Technology, LLC which advises several biotech firms on strategic and technical matters in pharmaceutical R&D. Dr. Farina currently serves as the Co-Chair and Board Member of Connecticut United for Research Excellence (CURE); the Advisory Board of the University of Connecticut School of Pharmacy, member of the NIH Blueprint Neurotherapeutics Network (BPN) steering committee; Emory University DRIVE Advisory Board, and was a Founder and CEO of Developing World Cures, a nonprofit company working on neglected diseases.
Professor Dianqing (Dan) WU, PhD
Dr. WU is the Professor of Pharmacology at the Yale School of Medicine. He also is the adjunct professor of Department of Genetics and Developmental Biology, University of Connecticut. He focuses on studying signal transduction pathways.
Dr. Renxiang TAN
Dr. TAN is a Professor of Nanjing University. He is also a winner of National Outstanding Youth Fund in 1998, Distinguished
Professor of the Cheung Kong scholars program in 1999. With his leadership applying multidisciplinary advanced technologies,
the project team found that a series of active ingredients that led to an antidepressant candidate that is currently under a Phase II
clinical study. Because of his innovative research work, the project "Significant Research Achievements on the Ingredients of
Medicinal Plants” won the second prize of National Natural Science Award in 2009.
Dr Chengyu ZHANG
Dr. ZHANG is a Professor and the Dean of the School of Life Science, Nanjing University, national outstanding youth fund gainer (2003), Distinguished Professor of Cheung Kong Scholars Program in 2004, National Pacesetter Plan in 2009, Jiangsu Province Ten Outstanding Youth in 2006, Tan Jiazheng Life Science Innovation Award winner in 2008, as a chief scientist for National "973" and"863" Projects.His research is focused in the field of molecular mechanism of Cell energy metabolism and its related disease pathogenesis. He has a total of 60 publications on the prestige journals including Cell, Nature and Science.
Dr. Yao YAO
Dr. YAO is currently the Vice President of Quality Assurance and Regulatory Affairs of HLK. She also is the Associate Director of
Pharmaceutical Technology Institute, Shenzhen Research Institute of NanjingUniversity. Prior to current positions, YAO was the
manager of Regulatory Affairs and Clinical Quality Assurance at Teva Pharmaceuticals. Her responsibilities included, but not limited
to, designing and managing regulatory strategies for drug development, reviewing and submitting marketing applications (IND, NDA,
BLA, and ANDA), and providing compliance guidance and conduct quality audits.
(5) General Administrative Office
Office Manager: Ms. Xuelan LIN
5. Contact Information
Address: No. 6 Yuexing 3rd road, Southern District of Shenzhen High-tech Industrial Park, Nanshan District, Shenzhen, P.R. China.
Phone: +86 755-86007001
Email: info@hlkpharma.com, lin040201@njusz.com
电话：0755-61865676 传真：0755-61865696 邮箱：oa@njusz.org.cn
技术支持：35互联
| 
深圳研究院 |